Inclusion Criteria:  0-39yrs T-cell ALL in second or subsequent remission (≤ 5% blasts) or relapsed T-cell LLy with complete response after re-induction therapy Planned allogeneic stem cell transplantation with donor identified Performance status ≥ 60% Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study Meet organ function requirements Signed IRB approved informed consent  Exclusion Criteria:  May not have had a prior autologous or allogenic stem cell transplant May not have uncontrolled, systemic infection at the time of enrollment Known allergies, hypersensitivity, or intolerance to mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients Must not be pregnant or actively breast feeding Seropositive for HIV, hepatitis B or hepatitis C COPD Asthma Clinically significant cardiac disease